Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A double blind, randomized and placebo-controlled clinical trial with naltrexone and brief intervention in outpatient treatment of alcohol dependence

Full text
Author(s):
Luís André Castro [1] ; Ronaldo Laranjeira [2]
Total Authors: 2
Affiliation:
[1] Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Psiquiatria - Brasil
[2] Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Psiquiatria
Total Affiliations: 2
Document type: Journal article
Source: Jornal Brasileiro de Psiquiatria; v. 58, n. 2, p. 79-85, 2009-00-00.
Field of knowledge: Health Sciences - Medicine
Abstract

OBJECTIVE: The objective of this study is to evaluate the efficacy of naltrexone with brief intervention among patients with alcohol dependence. METHOD: This study is a 12-week randomized, double blind, placebo-controlled clinical trial. The sample of 71 patients was randomly divided in two groups (one receiving naltrexone and the other placebo). Alcohol-dependent subjects were treated with 50 mg of naltrexone or placebo daily for 12 weeks. Both treatment groups received brief intervention. The primary results for this study were relapse rate and change in drinking behaviors. RESULTS: In the intention-to-treat fewer naltrexone treated subjects relapsed (3% 21%; p = 0.054). Naltrexone with brief intervention was not effective in decreasing drinking days (6.2 + 10.6 3.05 + 7.3; p = 0.478), moderate drinking days (0 2.2 + 6.9; p = 0.345) and heavy drinking days (0.03 + 0.2 0.3 + 0.9; p = 0.887). Naltrexone was well tolerated. The most frequent adverse effects in our sample were: headache (25.4%), drowsiness (20.9%), nausea (16.4%), hyperphagia (16.4%), anorexia (14.9%), anxiety (10.4%), heartburn (10.4%) and irritability (10.4%). CONCLUSIONS: Although the naltrexone group showed a tendency to reduce relapse rate (> 5 drinks/day), no differences were found in other alcohol consumption variables between naltrexone and placebo groups. Further studies should examine the efficacy of this kind of treatment combination in the primary health care. (AU)